ABCL logo

AbCellera Biologics Inc. (ABCL) Cash From Financing

Annual CFF:

$12.77M+$2.41M(+23.30%)
December 31, 2024

Summary

  • As of today, ABCL annual cash from financing is $12.77 million, with the most recent change of +$2.41 million (+23.30%) on December 31, 2024.
  • During the last 3 years, ABCL annual cash from financing has risen by +$16.66 million (+428.59%).
  • ABCL annual cash from financing is now -98.13% below its all-time high of $683.65 million, reached on December 31, 2020.

Performance

1-Year Change

+23.3%

3-Year Change

+428.59%

5-Year Change

+6448.21%

15-Year Change

+4.78%

ABCL Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Percentile

57.8%
ABCL annual cash from financing is higher than 57.8% of companies in Healthcare sector

Range

All-Time High

$683.65M
ABCL annual cash from financing is currently -98.13% below its historical high of $683.65 million

3-Year Low

-$3.89M
ABCL annual cash from financing is currently +428.59% above its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2024
ABCL previous annual earnings announcement was published on Dec 31, 2024

Next Annual Earnings Report Date

N/A
ABCL next annual earnings announcement has not yet been scheduled

OtherABCLcash flow metrics

Annual CFI

$121.41M
ABCL annual cash from investing is $121.41 million

Annual CFO

-$108.56M
ABCL annual cash from operations is -$108.56 million

Annual FCF

-$186.95M
ABCL annual free cash flow is -$186.95 million

Annual CAPEX

$78.40M
ABCL annual capital expenditures is $78.40 million

Quarterly CFF:

-$3.33M-$9.30M(-155.74%)
June 1, 2025

Summary

  • As of today, ABCL quarterly cash from financing is -$3.33 million, with the most recent change of -$9.30 million (-155.74%) on June 1, 2025.
  • Over the past year, ABCL quarterly cash from financing has dropped by -$5.94 million (-227.39%).
  • ABCL quarterly cash from financing is now -100.53% below its all-time high of $629.01 million, reached on December 31, 2020.

Performance

3-Month Change

-155.74%

1-Year Change

-227.39%

3-Year Change

-381.79%

5-Year Change

-1061.73%

ABCL Quarterly Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Percentile

16.93%
ABCL quarterly cash from financing is higher than 16.93% of companies in Healthcare sector

Range

All-Time High

$629.01M
ABCL quarterly cash from financing is currently -100.53% below its historical high of $629.01 million

3-Year Low

-$3.33M
ABCL quarterly cash from financing is currently at its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Jun 1, 2025
ABCL previous earnings announcement was published on Jun 1, 2025

Next Quarterly Earnings Report Date

Nov 6, 2025
ABCL next earnings announcement is scheduled for Nov 6, 2025

OtherABCLcash flow metrics

Quarterly CFI

-$32.25M
ABCL quarterly cash from investing is -$32.25 million

Quarterly CFO

-$33.21M
ABCL quarterly cash from operations is -$33.21 million

Quarterly FCF

-$47.01M
ABCL quarterly free cash flow is -$47.01 million

Quarterly CAPEX

$13.80M
ABCL quarterly capital expenditures is $13.80 million

TTM CFF:

$9.71M-$5.94M(-37.96%)
June 1, 2025

Summary

  • As of today, ABCL TTM cash from financing is $9.71 million, with the most recent change of -$5.94 million (-37.96%) on June 1, 2025.
  • Over the past year, ABCL TTM cash from financing has dropped by -$6.04 million (-38.34%).
  • ABCL TTM cash from financing is now -98.62% below its all-time high of $705.00 million, reached on December 31, 2020.

Performance

3-Month Change

-37.96%

1-Year Change

-38.34%

3-Year Change

+971.65%

5-Year Change

-87.22%

ABCL TTM Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Percentile

57.31%
ABCL TTM cash from financing is higher than 57.31% of companies in Healthcare sector

Range

All-Time High

$705.00M
ABCL TTM cash from financing is currently -98.62% below its historical high of $705.00 million

3-Year Low

-$1.56M
ABCL TTM cash from financing is currently +721.88% above its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Jun 1, 2025
ABCL previous earnings announcement was published on Jun 1, 2025

Next Quarterly Earnings Report Date

Nov 6, 2025
ABCL next earnings announcement is scheduled for Nov 6, 2025

OtherABCLcash flow metrics

TTM CFI

$13.20M
ABCL TTM cash from investing is $13.20 million

TTM CFO

-$79.94M
ABCL TTM cash from operations is -$79.94 million

TTM FCF

-$137.24M
ABCL TTM free cash flow is -$137.24 million

TTM CAPEX

$57.30M
ABCL TTM capital expenditures is $57.30 million

Cash From Financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

ABCL Cash From Financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year+23.3%-227.4%-38.3%
3Y3 Years+428.6%-381.8%+971.6%
5Y5 Years+6448.2%-1061.7%-87.2%

ABCL Cash From Financing Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Yearat high+428.6%-150.0%at low-38.3%+721.9%
5Y5-Year-98.1%+428.6%-100.5%+72.5%-98.6%+278.0%
All-TimeAll-Time-98.1%+428.6%-100.5%+72.5%-98.6%+278.0%

ABCL Cash From Financing History

DateAnnualQuarterlyTTM
Jun 2025
-
-$3.33M(-155.7%)
$9.71M(-38.0%)
Mar 2025
-
$5.97M(+52.5%)
$15.65M(+25.1%)
Dec 2024
$12.77M(+23.3%)
$3.92M(+24.3%)
$12.51M(+2.2%)
Sep 2024
-
$3.15M(+20.6%)
$12.24M(-22.3%)
Jun 2024
-
$2.61M(-7.7%)
$15.74M(+16.2%)
Mar 2024
-
$2.83M(-22.3%)
$13.55M(+32.0%)
Dec 2023
$10.36M(+736.1%)
$3.64M(-45.3%)
$10.26M(+46.6%)
Sep 2023
-
$6.66M(+1489.4%)
$7.00M(+1900.5%)
Jun 2023
-
$418.90K(+191.5%)
$349.90K(-68.5%)
Mar 2023
-
-$458.00K(-220.2%)
$1.11M(+171.2%)
Dec 2022
-$1.63M
$380.90K(+4602.5%)
-$1.56M(-1290.1%)
Sep 2022
-
$8100.00(-99.3%)
-$112.30K(-112.4%)
DateAnnualQuarterlyTTM
Jun 2022
-
$1.18M(+137.7%)
$905.90K(+116.6%)
Mar 2022
-
-$3.13M(-271.1%)
-$5.45M(-41.1%)
Dec 2021
-$3.89M(-100.6%)
$1.83M(+78.3%)
-$3.86M(-100.6%)
Sep 2021
-
$1.03M(+119.8%)
$623.31M(+2.1%)
Jun 2021
-
-$5.18M(-235.6%)
$610.19M(-0.9%)
Mar 2021
-
-$1.54M(-100.2%)
$615.72M(-12.7%)
Dec 2020
$683.65M(>+9900.0%)
$629.01M(+5301.7%)
$705.00M(+827.7%)
Sep 2020
-
-$12.09M(-3594.9%)
$75.99M(-13.7%)
Jun 2020
-
$346.00K(-99.6%)
$88.08M(+0.4%)
Mar 2020
-
$87.74M
$87.74M
Dec 2019
$195.00K(-98.4%)
-
-
Dec 2018
$12.19M
-
-

FAQ

  • What is AbCellera Biologics Inc. annual cash from financing?
  • What is the all-time high annual cash from financing for AbCellera Biologics Inc.?
  • What is AbCellera Biologics Inc. annual cash from financing year-on-year change?
  • What is AbCellera Biologics Inc. quarterly cash from financing?
  • What is the all-time high quarterly cash from financing for AbCellera Biologics Inc.?
  • What is AbCellera Biologics Inc. quarterly cash from financing year-on-year change?
  • What is AbCellera Biologics Inc. TTM cash from financing?
  • What is the all-time high TTM cash from financing for AbCellera Biologics Inc.?
  • What is AbCellera Biologics Inc. TTM cash from financing year-on-year change?

What is AbCellera Biologics Inc. annual cash from financing?

The current annual cash from financing of ABCL is $12.77M

What is the all-time high annual cash from financing for AbCellera Biologics Inc.?

AbCellera Biologics Inc. all-time high annual cash from financing is $683.65M

What is AbCellera Biologics Inc. annual cash from financing year-on-year change?

Over the past year, ABCL annual cash from financing has changed by +$2.41M (+23.30%)

What is AbCellera Biologics Inc. quarterly cash from financing?

The current quarterly cash from financing of ABCL is -$3.33M

What is the all-time high quarterly cash from financing for AbCellera Biologics Inc.?

AbCellera Biologics Inc. all-time high quarterly cash from financing is $629.01M

What is AbCellera Biologics Inc. quarterly cash from financing year-on-year change?

Over the past year, ABCL quarterly cash from financing has changed by -$5.94M (-227.39%)

What is AbCellera Biologics Inc. TTM cash from financing?

The current TTM cash from financing of ABCL is $9.71M

What is the all-time high TTM cash from financing for AbCellera Biologics Inc.?

AbCellera Biologics Inc. all-time high TTM cash from financing is $705.00M

What is AbCellera Biologics Inc. TTM cash from financing year-on-year change?

Over the past year, ABCL TTM cash from financing has changed by -$6.04M (-38.34%)
On this page